Determinants of antileukemia effects of allogeneic NK cells.
about
Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic DisordersCord Blood as a Source of Natural Killer CellsEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityNK cell therapy: targeting disease relapse after hematopoietic stem cell transplantationManufacturing Natural Killer Cells as Medicinal ProductsCytotoxicity of activated natural killer cells against pediatric solid tumors.Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs.Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.Immunotherapy in acute leukemiaImproved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantationEffects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockadeDonor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantationBiology and clinical effects of natural killer cells in allogeneic transplantation.Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donorOpportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseKIR diversity in Māori and Polynesians: populations in which HLA-B is not a significant KIR ligand.KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantationKIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cellsActivating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.Natural killer cell engineering for cellular therapy of cancerNK cell-based immunotherapies in Pediatric Oncology.HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemiaDonor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Use of natural killer cells in hematopoetic stem cell transplantation.Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.MHC class I molecules and KIRs in human history, health and survival.Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.Natural killer cell therapy in children with relapsed leukemia.
P2860
Q26767501-197649E6-62AB-4579-862A-7EA89D6599D4Q26771337-24F498ED-B25A-43C5-901D-8886937FC41DQ26796313-7400C942-6DC7-4802-8130-4E7038FB7735Q26863559-F8BF6452-D01C-44E5-899A-CA10389798C5Q28069992-5618E1E9-F2AD-4125-8CA2-0C306DE846A4Q30503995-E98408A3-3A56-4139-A957-9390A17CC376Q33378868-2E520FF1-818C-41DD-837E-55DE28EACE90Q33605294-2974F311-5425-4617-8002-A04A175DEE67Q33672480-820215F2-E33A-418B-AECF-764FF4230866Q33710760-0824B638-DDFD-4B75-8372-E16E61E08FC8Q33731552-48523F90-C370-41A8-A2DD-E710C6909D66Q33765556-79FEDBEE-2D1E-4A1E-BF45-03C7947E207CQ33777096-6B524F27-6E6A-4290-B596-E8D0ECB27D7AQ33787859-B474732C-76F2-463E-A3D7-DC9A029C76E6Q33805980-9B6327F3-AD59-44E8-88E7-527BBBC6C986Q33893173-32C0C80C-15D1-47A4-B432-EDF5DCADDA34Q34087767-8E36A94C-5B8E-41BD-A722-3EC049E420C1Q34193507-A87BABA7-C4A5-4EFC-9BB8-317F74B12A0CQ34231837-E369259C-DB08-494F-BA0E-287C5270996EQ34307792-9E2C1326-FC31-4354-AACA-66FA7E676A49Q34345310-6094F43B-1DA2-4127-86CC-CDE8EFC5160AQ34398420-5818749F-1BAF-42FE-9A95-0BFAD99CA6FEQ34618829-2BA5FDA6-9559-4B26-A338-25D535BF6AECQ34840348-579843FE-FA67-4AA9-BEF0-849283CE693CQ35083496-C45B9C98-B498-4F89-99EC-4659EFDAA887Q35112199-A61A45F9-51BE-4955-B206-3336083EF9C8Q35556865-6E2D4340-89E0-491C-AA77-4009462D0E89Q35600975-790D76C6-6BA4-412E-8125-8830364159B8Q35678422-887C628A-B28D-42C8-8886-8DC209D78732Q35828810-F46B8A5C-C781-40FD-9DE5-946905EF871BQ35847425-D720E4CC-DBD3-4A4B-A562-AC9206C6F52EQ35847820-1F3951E3-B775-45FC-B98A-84710DB1B1D3Q35850044-5EF12E94-12B8-4458-8DCC-F7C80D8A83DEQ35850712-F4B9229A-CA06-41FA-B23A-3A21B761DFC0Q35963440-2647EA37-241E-4BC9-99BB-62ED05824F3DQ36011664-4D5E5AA2-D126-4E37-897F-851E0A478813Q36045773-B69C2D8A-2881-4F38-9CEA-4D2012CE1C74Q36047157-609FB8BD-CF17-4906-9B4F-DD4BF587AB3DQ36061068-155F9F5A-C41D-4447-9A5F-B2FF8A6213A3Q36251948-43EB2DD7-5F71-4D5B-BB6B-0AE913B7B2FE
P2860
Determinants of antileukemia effects of allogeneic NK cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Determinants of antileukemia effects of allogeneic NK cells.
@en
type
label
Determinants of antileukemia effects of allogeneic NK cells.
@en
prefLabel
Determinants of antileukemia effects of allogeneic NK cells.
@en
P2093
P1476
Determinants of antileukemia effects of allogeneic NK cells.
@en
P2093
Dietrich Niethammer
Peter Bader
Peter Lang
Rekha Iyengar
Rupert Handgretinger
Victoria Turner
Wing Leung
P304
P356
10.4049/JIMMUNOL.172.1.644
P407
P577
2004-01-01T00:00:00Z